Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Jansen underscores the need for urologists to go beyond symptom treatment and focus on identifying root causes of testosterone deficiency.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact ...

Data from the phase 2 EXTEND trial showed that the addition of metastasis-directed therapy to ADT improved measures of systemic disease control.

Updated data from the phase 3 ENVISION trial (NCT05243550) point to sustained efficacy of mitomycin for intravesical solution (Zusduri; formerly UGN-102) in patients with recurrent low-grade, ...

The phase 1/2 CaRe PC trial (NCT06056791) assessing INKmune in patients with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary end points, INmune Bio reported ...

Data from the phase 3b study were recently published in Reviews in Urology, showing that administration of mitomycin intravesical solution in the home setting was feasible, safe, and effective.

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

In this interview, Daniel D. Joyce, MD, MS, assistant professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee, discusses the economic and clinical considerations of using ...

One consideration is the setting in which the procedure is performed. The FDA recently expanded the label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, In this interview, ...

Howard B. Goldman, MD, who was the first to use the device in a clinical setting, shares his initial thoughts on the technology and its role in real-world practice.

TAR-200, an intravesical gemcitabine-releasing system, targets BCG-unresponsive high-risk NMIBC with CIS, showing an 82.4% complete response rate in the SunRISe-1 trial. The treatment demonstrated a ...